MX2021009404A - Administracion del virus adenoasociado de polinucleotido de cln6. - Google Patents
Administracion del virus adenoasociado de polinucleotido de cln6.Info
- Publication number
- MX2021009404A MX2021009404A MX2021009404A MX2021009404A MX2021009404A MX 2021009404 A MX2021009404 A MX 2021009404A MX 2021009404 A MX2021009404 A MX 2021009404A MX 2021009404 A MX2021009404 A MX 2021009404A MX 2021009404 A MX2021009404 A MX 2021009404A
- Authority
- MX
- Mexico
- Prior art keywords
- cln6
- administration
- associated virus
- polynuclotide
- adeno associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800915P | 2019-02-04 | 2019-02-04 | |
| US201962880641P | 2019-07-30 | 2019-07-30 | |
| US201962881151P | 2019-07-31 | 2019-07-31 | |
| US201962912977P | 2019-10-09 | 2019-10-09 | |
| US201962923125P | 2019-10-18 | 2019-10-18 | |
| PCT/US2020/016541 WO2020163299A1 (en) | 2019-02-04 | 2020-02-04 | Adeno-associated virus delivery of cln6 polynucleotide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009404A true MX2021009404A (es) | 2021-11-12 |
Family
ID=69771088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009404A MX2021009404A (es) | 2019-02-04 | 2020-02-04 | Administracion del virus adenoasociado de polinucleotido de cln6. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220202956A1 (https=) |
| EP (1) | EP3921429A1 (https=) |
| JP (2) | JP2022519597A (https=) |
| KR (1) | KR20210124299A (https=) |
| CN (2) | CN113574176B (https=) |
| AU (1) | AU2020218501B2 (https=) |
| BR (1) | BR112021015150A2 (https=) |
| CA (1) | CA3127801A1 (https=) |
| CL (1) | CL2021002051A1 (https=) |
| IL (1) | IL285329A (https=) |
| MX (1) | MX2021009404A (https=) |
| SG (1) | SG11202107983TA (https=) |
| TW (1) | TW202033768A (https=) |
| WO (1) | WO2020163299A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013296425B2 (en) | 2012-08-01 | 2018-06-07 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| CA3137080A1 (en) * | 2019-04-15 | 2020-10-22 | Sanford Research | Gene therapy for treating or preventing visual effects in batten disease |
| WO2023018674A1 (en) * | 2021-08-09 | 2023-02-16 | Amicus Therapeutics, Inc. | Determination of gene transduction potency in neuron-like cells |
| WO2026039311A1 (en) | 2024-08-10 | 2026-02-19 | Vectorgen | Lentiviral vector for treating human immunodeficiency virus infection |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU613316B2 (en) * | 1986-09-12 | 1991-08-01 | Genentech Inc. | Improved recombinant expression |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1995013365A1 (en) | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
| PT728214E (pt) | 1993-11-09 | 2004-11-30 | Ohio Med College | Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| SE9403613D0 (sv) * | 1994-10-21 | 1994-10-21 | Pharmacia Ab | Improvement of an expression vector for production of recombinant proteins |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| CA2207927A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| US6632670B1 (en) | 1995-09-08 | 2003-10-14 | Genzyme Corporation | AAV vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| JP2001500497A (ja) | 1996-09-06 | 2001-01-16 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスに指図される遺伝子治療の方法 |
| DK1009808T3 (da) | 1997-09-05 | 2013-01-21 | Genzyme Corp | Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| US7056502B2 (en) | 2000-04-28 | 2006-06-06 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids |
| JP3765574B2 (ja) * | 2001-02-22 | 2006-04-12 | 三菱化学株式会社 | 逆向き反復配列を含む組み換え遺伝子及びその利用 |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| AU2013296425B2 (en) * | 2012-08-01 | 2018-06-07 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| US9943611B2 (en) * | 2012-11-01 | 2018-04-17 | California Institute Of Technology | Reversible gene expression |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| WO2016100575A1 (en) * | 2014-12-16 | 2016-06-23 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| CA3011939A1 (en) * | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
| EP3411484B1 (en) * | 2016-02-05 | 2023-10-04 | Emory University | Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid |
-
2020
- 2020-02-04 JP JP2021545402A patent/JP2022519597A/ja active Pending
- 2020-02-04 TW TW109103421A patent/TW202033768A/zh unknown
- 2020-02-04 WO PCT/US2020/016541 patent/WO2020163299A1/en not_active Ceased
- 2020-02-04 US US17/426,993 patent/US20220202956A1/en active Pending
- 2020-02-04 KR KR1020217027481A patent/KR20210124299A/ko active Pending
- 2020-02-04 SG SG11202107983TA patent/SG11202107983TA/en unknown
- 2020-02-04 CA CA3127801A patent/CA3127801A1/en active Pending
- 2020-02-04 MX MX2021009404A patent/MX2021009404A/es unknown
- 2020-02-04 AU AU2020218501A patent/AU2020218501B2/en active Active
- 2020-02-04 EP EP20709849.2A patent/EP3921429A1/en active Pending
- 2020-02-04 CN CN202080012159.9A patent/CN113574176B/zh active Active
- 2020-02-04 CN CN202510650084.1A patent/CN120505372A/zh active Pending
- 2020-02-04 BR BR112021015150-8A patent/BR112021015150A2/pt unknown
-
2021
- 2021-08-03 IL IL285329A patent/IL285329A/en unknown
- 2021-08-03 CL CL2021002051A patent/CL2021002051A1/es unknown
-
2025
- 2025-02-17 JP JP2025023029A patent/JP2025093922A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3127801A1 (en) | 2020-08-13 |
| IL285329A (en) | 2021-09-30 |
| TW202033768A (zh) | 2020-09-16 |
| EP3921429A1 (en) | 2021-12-15 |
| US20220202956A1 (en) | 2022-06-30 |
| AU2020218501A1 (en) | 2021-08-19 |
| AU2020218501B2 (en) | 2026-01-29 |
| CL2021002051A1 (es) | 2022-04-08 |
| SG11202107983TA (en) | 2021-08-30 |
| CN113574176B (zh) | 2025-06-06 |
| JP2022519597A (ja) | 2022-03-24 |
| JP2025093922A (ja) | 2025-06-24 |
| BR112021015150A2 (pt) | 2021-09-28 |
| CN113574176A (zh) | 2021-10-29 |
| CN120505372A (zh) | 2025-08-19 |
| WO2020163299A1 (en) | 2020-08-13 |
| KR20210124299A (ko) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002051A1 (es) | Administración del virus adenoasociado de polinucleótido de cln6. | |
| Skvarc et al. | The effect of N-acetylcysteine (NAC) on human cognition–A systematic review | |
| MX2021009401A (es) | Administracion de virus adenoasociado de polinucleotido de cln3. | |
| MX2018012605A (es) | Administracion de vectores del virus adenoasociado de b-sarcoglicano y microarn-29 y el tratamiento de la distrofia muscular. | |
| CO2020006148A2 (es) | Métodos y materiales para terapia génica con nt-3 | |
| EP4327873A3 (en) | Tpp1 formulations and methods for treating cln2 disease | |
| MX2019007873A (es) | Terapia génica para tratar la enfermedad de wilson. | |
| MX2021005517A (es) | Terapia genica para lipofuscinosis neuronal ceroidea. | |
| MX2020004005A (es) | Terapias genicas para los trastornos lisosomales. | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
| RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
| EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута | |
| CU20160088A7 (es) | Piperidinil-tetrahidroquinolinas sustituidas | |
| MX2019011965A (es) | Composiciones de medicamentos a base de peptido de colageno y metodos y dispositivos para su produccion y uso. | |
| CR20160277A (es) | Piperidinil tetrahidroquinolinas sustituidas | |
| BR112019009511A2 (pt) | polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento. | |
| WO2016040169A3 (en) | Mucolytic agents for use in tretaing pulmonary sarcoidosis | |
| MX2017015292A (es) | Composicion para tratar lesiones cerebrales. | |
| MX2024010980A (es) | Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor | |
| CL2021003337A1 (es) | Tratamiento de la insuficiencia cardíaca en individuos humanos. | |
| PE20201166A1 (es) | Metodos y composiciones para tratar enfermedades pulmonares cronicas | |
| CO2020014399A2 (es) | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida | |
| AR124827A1 (es) | Suministro por virus adeno-asociado de polinucleótido cln3 | |
| MX2022002451A (es) | Metodos para el tratamiento de la enfermedad cln2 en sujetos pediatricos. |